Scarica l'app Stockscreener
465.89
0.57%
-2.69
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$468.58
Aprire:
$468.29
Volume 24 ore:
636.08K
Relative Volume:
0.59
Capitalizzazione di mercato:
$61.07B
Reddito:
$2.46B
Utile/perdita netta:
$-319.09M
Rapporto P/E:
-188.62
EPS:
-2.47
Flusso di cassa netto:
$-52.09M
1 W Prestazione:
+3.07%
1M Prestazione:
+8.36%
6M Prestazione:
+92.18%
1 anno Prestazione:
+78.00%
Intervallo 1D:
$465.48
$475.69
Intervallo di 1 settimana:
$452.85
$484.21
Portata 52W:
$205.87
$484.21
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Lowers Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
EP Wealth Advisors LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Voleon Capital Management LP - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
SCS Capital Management LLC Invests $46.19 Million in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Colleen Reitan Sells 18,000 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock - MarketBeat
Assessing Alnylam After Stock Surges 100% on RNAi Momentum in 2025 - simplywall.st
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $515.05 - MarketBeat
Alnylam Pharma Announces $500M Convertible Notes Offering - MSN
Will Positive HELIOS-B Data and $575 Million Offering Transform Alnylam’s (ALNY) RNAi Therapy Narrative? - Yahoo Finance
Plato Investment Management Ltd Has $1.27 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Pfizer, Alnylam earn BridgeBio ire over sales tactics for amyloidosis drugs: Bloomberg - Seeking Alpha
Woodline Partners LP Invests $42.25 Million in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Parkman Healthcare Partners LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Jacobs Levy Equity Management Inc. Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Top Pharmaceutical Stocks To Follow TodaySeptember 10th - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 1-Year HighShould You Buy? - MarketBeat
BridgeBio Says Pfizer, Alnylam Aren’t Playing Fair in Blockbuster Race - Bloomberg.com
Alnylam prices $575M convertible senior notes - MSN
Pharmaceutical Stocks To Add to Your WatchlistSeptember 9th - MarketBeat
Alnylam at Morgan Stanley Healthcare: Strategic Growth and Challenges - Investing.com
HC Wainwright Analysts Increase Earnings Estimates for ALNY - MarketBeat
Hereditary Transthyretin Amyloidosis (hATTR) Market New Product Development & Latest Trends - openPR.com
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains? - Yahoo Finance
Alnylam announces proposed offering of $500M convertible senior notes - MSN
Focus Partners Advisor Solutions LLC Increases Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam prices $575 million convertible notes offering - Investing.com
Alnylam announces pricing of upsized offering of $575 million convertible senior notes due 2028 - MarketScreener
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes - Business Wire
Eventide Asset Management LLC Sells 73,968 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Cinctive Capital Management LP - MarketBeat
Alnylam Pharmaceuticals stock hits all-time high at 470.0 USD By Investing.com - Investing.com South Africa
Alnylam Pharmaceuticals stock hits all-time high at 470.0 USD - Investing.com
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After HELIOS-B Study Reveals Long-Term AMVUTTRA Benefits - simplywall.st
Alnylam (ALNY) should rally into $479-$494 before correction start - FXStreet
Scenic Biotech Appoints Dr. Roland W. Bürli as CSO to Advance Pipeline of Modifier Therapies in Neuro- and Metabolic Diseases - GlobeNewswire Inc.
Alnylam commences $500 million convertible notes offering - Investing.com
Alnylam Launches $500 Million Convertible Notes Offering - MarketScreener
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes - Business Wire
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth? - sharewise.com
BMO Capital raises Alnylam Pharmaceuticals stock price target on Zilebesiran potential - Investing.com Canada
HC Wainwright Reaffirms "Buy" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Bridger Management LLC Has $9.44 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Canada Pension Plan Investment Board - MarketBeat
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Positive Long-Term HELIOS-B Results for AMVUTTRA - simplywall.st
Is Alnylam Pharmaceuticals Inc. a defensive stockJuly 2025 Momentum & Reliable Breakout Stock Forecasts - خودرو بانک
Is Alnylam Pharmaceuticals Inc. exposed to political riskJuly 2025 Decliners & Community Consensus Trade Signals - خودرو بانک
What are Alnylam Pharmaceuticals Inc.’s earnings expectationsEarnings Beat & Safe Entry Point Alerts - خودرو بانک
OMERS ADMINISTRATION Corp Decreases Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Intraday pattern recognizer results for Alnylam Pharmaceuticals Inc.2025 Trading Volume Trends & Expert Approved Momentum Trade Ideas - Newser
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.44%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):